Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Johnson and Johnson arm announces initiation of coronary artery trial

Johnson and Johnson arm announces initiation of coronary artery trial

4th September 2009

Johnson and Johnson company the Cordis Corporation has announced the opening and first registration of a trail designed to investigate the effects of dual anti-platelet therapy following the administering of a CYPHER Sirolimus-eluting Coronary Stent.

Designed to encompass a wide range of patients with coronary artery disease, the CYPRESS (cypherr for evaluating sustained safety) trial has received its first candidate.

It will provide data to support the clinical evaluation of Crodis’ new NEVO Sirolimus-eluting Coronary Stent in the NEVO III study, a non-randomised, single-arm trial evaluating the clinical outcomes of NEVO in 1,200 patients.

“CYPRESS will be used to support our pre-market approval application in the U.S. for NEVO, which we believe has the potential to return Cordis to global leadership in the drug-eluting stent market,” said Campbell Rogers, chief scientific officer and global head of research and development at Cordis.

Meanwhile, Cordis’ parent company Johnson and Johnson released a report detailing the extent to which it met its sustainability goals in 2008, marking the sixth year the company has published such a paper.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.